<DOC>
	<DOCNO>NCT01055340</DOCNO>
	<brief_summary>This study test hypotheses single dose oxyntomodulin ( OXM ) neutral well placebo lower ambient glucose level grade glucose infusion ( GGI ) single dose OXM lead statistically significant increase sum plasma βOHB + AcAc level compare placebo .</brief_summary>
	<brief_title>A Study That Will Evaluate Ketogenesis Glucose-Dependent Insulin Secretion Methodologies Healthy Male Subjects ( MK-0000-159 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Insulin</mesh_term>
	<criteria>Subject judge good health base medical history , physical examination , laboratory safety test Subject Body Mass Index ≥27 kg/m^2 ≤35 kg/m^2 weighs ≥70 kg prestudy ( screen ) visit Subject nonsmoker and/or use nicotine nicotinecontaining product least approximately 6 month Subject willing avoid strenuous physical activity ( weight lifting , run , bicycling , etc . ) duration study Subject mentally legally incapacitate , significant emotional problem time prestudy ( screen ) visit Subject history stroke , chronic seizure , major neurological disorder Subject history clinically significant endocrine , gastrointestinal , cardiovascular , hematological , hepatic , immunological , renal , respiratory , genitourinary abnormality diseases Subject irritable bowel disease , recurrent occurrence nausea , vomit , diarrhea , abdominal pain Subject history hypertension require treatment Subject history cancer Subject history diabetes , family history diabetes mellitus Subject history hypersensitivity OXM hemaccel</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Ketogenesis</keyword>
	<keyword>Glucose-Dependent Insulin Secretion</keyword>
	<keyword>Graded Glucose Infusion</keyword>
	<keyword>Oxyntomodulin</keyword>
</DOC>